文献速递免疫规划传染病防控与疫情报告

2003至2014年荷兰人群流感疫苗效果估计:采用不同对照组设计的检测阴性设计病例对照研究

Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups.
PubMed 文献 · Vaccine · 2017-04-12

该研究利用荷兰NIVEL初级保健数据库哨点实践数据,纳入因急性流感样疾病或急性呼吸道感染就诊且已知流感疫苗接种状态的患者,采用检测阴性设计病例对照研究,将对照分为全部流感阴性、非流感病毒阳性(呼吸道合胞病毒、鼻病毒或肠道病毒阳性)和全阴性三组,估计2003/2004至2013/2014流行季的流感疫苗效果。调整年龄、全科医生诊断、慢性病和呼吸道过敏后,总体流感疫苗效果分别为35%(95%CI:15-48)、64%(95%CI:49-75)和21%(95%CI:-1至39),非流感病毒阳性对照组估计值最高,可能因该组对照均有实验室确认的引起呼吸道疾病的病毒。

要点

  • 非流感病毒阳性对照组的流感疫苗效果估计最高,为64%(95%CI:49-75)。
  • 全部流感阴性对照组和全阴性对照组的估计值分别为35%(95%CI:15-48)和21%(95%CI:-1至39)。
  • 对照组的定义可能影响流感疫苗效果估计,非流感病毒阳性对照限制未实验室确认病毒者的纳入。

核心结论

  • 在主要分析和亚组分析中,使用非流感病毒阳性对照组的流感疫苗效果估计值均最高,可能由于限制了无实验室确认引起呼吸道疾病病毒的对照者纳入。

研究设计与样本

  • 检测阴性设计病例对照研究,使用荷兰NIVEL初级保健数据库哨点实践数据,纳入因急性流感样疾病或急性呼吸道感染就诊且已知流感疫苗接种状态的患者。
  • 病例为流感病毒检测阳性患者;对照分为全部流感阴性、非流感病毒阳性(呼吸道合胞病毒、鼻病毒或肠道病毒阳性)和全阴性三组。
  • 估计2003/2004至2013/2014所有流行季的流感疫苗效果,并采用广义线性混合效应模型和多元逻辑回归模型合并部分/完全匹配季和不匹配季及单个流行季的估计值。

主要发现

  • 调整年龄、全科医生流感样疾病/急性呼吸道感染诊断、慢性病和呼吸道过敏后,总体流感疫苗效果在全部流感阴性对照组为35%(95%CI:15-48),在非流感病毒阳性对照组为64%(95%CI:49-75),在全阴性对照组为21%(95%CI:-1至39)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Information about influenza vaccine effectiveness (IVE) is important for vaccine strain selection and immunization policy decisions. The test-negative design (TND) case-control study is commonly used to obtain IVE estimates. However, the definition of the control patients may influence IVE estimates. We have conducted a TND study using the Dutch Sentinel Practices of NIVEL Primary Care Database which includes data from patients who consulted the General Practitioner (GP) for an episode of acute influenza-like illness (ILI) or acute respiratory infection (ARI) with known influenza vaccination status. Cases were patients tested positive for influenza virus. Controls were grouped into those who tested (1) negative for influenza virus (all influenza negative), (2) negative for influenza virus, but positive for respiratory syncytial virus, rhinovirus or enterovirus (non-influenza virus positive), and (3) negative for these four viruses (pan-negative). We estimated the IVE over all epidemic seasons from 2003/2004 through 2013/2014, pooled IVE for influenza vaccine partial/full matched and mismatched seasons and the individual seasons using generalized linear mixed-effect and multiple logistic regression models. The overall IVE adjusted for age, GP ILI/ARI diagnosis, chronic disease and respiratory allergy was 35% (95% CI: 15-48), 64% (95% CI: 49-75) and 21% (95% CI: -1 to 39) for all influenza negative, non-influenza virus positive and pan-negative controls, respectively. In both the main and subgroup analyses IVE estimates were the highest using non-influenza virus positive controls, likely due to limiting inclusion of controls without laboratory-confirmation of a virus causing the respiratory disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Doorn E, Darvishian M, Dijkstra F, et al. Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups. Vaccine. 2017. PMID: 28412077. doi:10.1016/j.vaccine.2017.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。